Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
More than 180 employees are innovating and mobilizing their talents, either by providing services or working in research and development. With beginner, experienced and senior profiles, more than 30% of which with a PhD, the teams made up of technicians and a Study Director work together to ensure the success of customer studies and our internal projects.